The core activity of NBE-Therapeutics AG is the development and research of therapeutics, particularly in the field of cancer treatment. The company focuses on the development of antibody-drug conjugates (ADCs) and other therapeutics targeting the fight against cancer cells.
AI-generated
Offering
Products & services
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Industry:Research & DevelopmentPharmaceutical Industry
✓ Offered7
Oncology treatments
Oncology treatments based on next-generation antibody-drug conjugates, developed to target solid tumors and improve survival and quality of life for cancer patients.
Antibody-drug conjugate technology
Antibody-drug conjugate platform combining monoclonal antibodies with small-molecule payloads, including tailored design of antibody, payload, DAR, conjugation site and homogeneity.
Site-specific conjugation
Enzymatic site-specific antibody conjugation with sortaseA transpeptidase, described as SMAC technology for antibody conjugation.
PNU anthracycline payload
Anthracycline-based payload for ADCs, described as a highly potent DNA-damaging intercalating toxin with picomolar potency.
Antibody discovery
Discovery of novel binders against new targets using a mammalian antibody library display system.